Healthcare >> CEO Interviews >> January 13, 2000
Earl M. 'Duke' Collier, is President of Genzyme Surgical Products. Duke
Collier joined Genzyme Corporation in 1997, though his relationship with
Genzyme, dates to 1990, when, as a consultant, he helped launch the
company's first major product, Ceredase. Mr. Collier currently serves as
executive vice president of Genzyme Corporation and as president of
Genzyme Surgical Products, a tracking stock division of Genzyme
Corporation that develops and markets a comprehensive portfolio of
instruments, devices, biomaterials and biotherapeutics primarily for the
cardiovascular and general surgery markets. Under Mr. Collier's
leadership, Genzyme Surgical Products is pioneering the emerging field
of biosurgery, which is being created by the increasing convergence of
mechanical and biological approaches to surgery and other interventional
procedures. Prior to joining Genzyme, Mr. Collier was a partner at the
Washington D.C. law firm of Hogan & Hartson. He has served as president
of Vitas Healthcare Corporation, and vice president, corporate
development and general counsel of Caremark, Inc. He also served as
deputy administrator of the Health Care Financing Administration. Mr.
Collier earned an A.B. at Yale University and a J.D. at the University
of Virginia Law School. He sits on the boards of CareTools, Inc. and
Beth Abraham Hospital. Profile
Mr. Collier: The history is pretty straightforward. We developed over a
number of years in our biomaterials laboratory the first
